Non Betallactum to drive API business growth: The Company expects the Semi Synthetic Penicillin and Cephalosporin API business to grow by 10%. A major chunk of the API segment growth will come from non betallactum APIs which have grown by 71.3% in Q1FY13. Management has guided for close to 50% and 30% sales growth for non betallactum APIs in FY13E and FY14E, respectively. Semi Synthetic Penicillin and Cephalosporin sterile APIs have been affected due to ban on Unit VI. USFDA inspecvtion of injectibles facility a silver lining: The company's Unit VI and IV facilities were recently inspected by the USFDA. We expect both the facilities to...